4.7 Review

Therapeutic Targeting of Endosomal G-Protein-Coupled Receptors

Journal

TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 39, Issue 10, Pages 879-891

Publisher

ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2018.08.003

Keywords

-

Funding

  1. National Institutes of Health [NS102722, DE026806, DK118971]
  2. Department of Defense [W81XWH1810431]
  3. U.S. Department of Defense (DOD) [W81XWH1810431] Funding Source: U.S. Department of Defense (DOD)

Ask authors/readers for more resources

G-protein-coupled receptors (GPCRs) are conventionally considered to function at the plasma membrane, where they detect extracellular ligands and activate heterotrimeric G proteins that transmit intracellular signals. Consequently, drug discovery efforts have focused on identification of agonists and antagonists of cell surface GPCRs. However, beta-arrestin (ARR)-dependent desensitization and endocytosis rapidly terminate G protein signaling at the plasma membrane. Emerging evidence indicates that GPCRs can continue to signal from endosomes by G-protein-and beta ARR-dependent processes. By regulating the duration and location of intracellular signaling events, GPCRs in endosomes control critically important processes, including gene transcription and ion channel activity. Thus, GPCRs in endosomes, in addition to at the cell surface, have emerged as important therapeutic targets.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available